替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的临床观察

柴松波; 杜亚康; 张淑娟; 兀江波; 张伟萍; 王晓飞

doi:10.6039/j.issn.1001-0408.2023.23.15

您当前的位置：

首页 >

文章列表页 >

替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的临床观察

药物与临床 | 更新时间：2023-12-08

- 替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的临床观察
- Clinical observation of ticagrelor combined with Compound xueshuantong capsule in the treatment of unstable angina pectoris
- 中国药房 2023年34卷第23期页码：2901-2905
- 作者机构：
  
  1.三门峡市中医院心病科，河南三门峡　472099
  2.河南中医药大学第二临床医学院心病科，郑州　450002
  3.三门峡市中医院药剂科，河南三门峡　472099
- 作者简介：
  
  副主任中医师，博士。研究方向：中医药防治心血管内科疾病的基础和临床研究。 E-mail：chaisongbosmx@163.com
- 基金信息：
  
  河南省中医药拔尖人才培养项目专项课题(2022ZYBJ29);河南省自然科学基金项目(212300410169)
- DOI：10.6039/j.issn.1001-0408.2023.23.15
  中图分类号： R972
- 纸质出版日期：2023-12-15，
  
  收稿日期：2023-05-29，
  
  修回日期：2023-11-02，
扫描看全文
柴松波,杜亚康,张淑娟等.替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的临床观察 ^Δ[J].中国药房,2023,34(23):2901-2905.

CHAI Songbo,DU Yakang,ZHANG Shujuan,et al.Clinical observation of ticagrelor combined with Compound xueshuantong capsule in the treatment of unstable angina pectoris[J].ZHONGGUO YAOFANG,2023,34(23):2901-2905.
柴松波,杜亚康,张淑娟等.替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的临床观察 ^Δ[J].中国药房,2023,34(23):2901-2905. DOI： 10.6039/j.issn.1001-0408.2023.23.15.

CHAI Songbo,DU Yakang,ZHANG Shujuan,et al.Clinical observation of ticagrelor combined with Compound xueshuantong capsule in the treatment of unstable angina pectoris[J].ZHONGGUO YAOFANG,2023,34(23):2901-2905. DOI： 10.6039/j.issn.1001-0408.2023.23.15.

摘要

目的

观察替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的疗效及安全性。

方法

将2021年1月－2022年12月三门峡市中医院收治的120例不稳定型心绞痛气阴两虚兼血瘀型患者随机分为氯吡格雷组（A组）、替格瑞洛组（B组）和联合用药组（C组），每组40例。A组患者在常规治疗基础上加用氯吡格雷口服；B组患者在常规治疗基础上加用替格瑞洛口服；C组患者在常规治疗基础上加用替格瑞洛和复方血栓通胶囊口服。治疗12周后评价3组患者的临床疗效、心绞痛发作情况、凝血功能指标、心功能指标、中医证候疗效、不良心血管事件和出血事件发生情况。

结果

A、B、C组患者的总有效率分别为77.5%、85.0%、90.0%，不良心血管事件和出血事件总发生率分别为7.5%、7.5%、5.0%，差异均无统计学意义（

＞0.05）。3组患者治疗后的心绞痛发作次数、心绞痛持续时间、气短持续时间均较治疗前显著减少或缩短（

＜0.05）；C组患者治疗后的心绞痛发作次数显著少于A、B组（

＜0.05）。3组患者治疗后的纤维蛋白原（FBG）、D-二聚体水平均显著低于治疗前（

＜0.05）；A组患者的FBG、D-二聚体水平显著高于B、C组（

＜0.05）。3组患者治疗后的左室收缩末期内径、左室舒张末期内径均显著短于治疗前，左室射血分数均显著高于治疗前（

＜0.05），但组间比较差异无统计学意义（

＞0.05）。A、B、C组患者的中医证候疗效总有效率分别为67.5%、80.0%、87.5%，其中C组显著高于A组（

＜0.05）。

结论

替格瑞洛联合复方血栓通胶囊可显著减少不稳定型心绞痛患者的心绞痛发作次数，降低FBG、D-二聚体水平，改善中医证候疗效，且不增加出血风险。

Abstract

OBJECTIVE

To observe the efficacy and safety of ticagrelor combined with Compound xueshuantong capsules in the treatment of unstable angina pectoris.

METHODS

Totally 120 patients with unstable angina pectoris with deficiency of Qi and Yin combined admitted to Sanmenxia Hospital of Traditional Chinese Medicine from January 2021 to December 2022 were randomly divided into clopidogrel group （group A）， ticagrelor group （group B） and combined medication group （group C）， with 40 patients in each group. In addition to conventional treatment， group A was given clopidogrel orally； group B was given ticagrelor orally； group C was given ticagrelor and Compound xueshuantong capsule orally. After 12 weeks of treatment， the clinical efficacy， frequency of angina attacks， coagulation function indicators， cardiac function indicators， traditional Chinese medicine syndrome efficacy， and the incidence of adverse cardiovascular events and bleeding incidence were evaluated in the 3 groups.

RESULTS

The total effective rates of group A， group B and group C were 77.5%， 85.0% and 90.0%， respectively. The incidence of adverse cardiovascular events and bleeding events were 7.5%， 7.5% and 5.0% in the respective groups， with no statistically significant difference （

＞0.05）. The frequency of angina attacks， duration of angina attacks and duration of dyspnea were significantly reduced or shortened in all 3 groups after treatment compared to before treatment （

＜0.05）. The frequency of angina attacks in group C was significantly lower than that in groups A and B after treatment （

＜0.05）. The levels of fibrinogen （FBG） and D-dimer in all 3 groups were significantly lower after treatment compared to before treatment （

＜0.05）； group A had significantly higher levels of FBG and D-dimer compared to group B and C （

＜0.05）. The left ventricular end-diastolic diameter and left ventricular end-systolic diameter in all three groups were significantly shorter after treatment， and the left ventricular ejection fraction was significantly higher compared to before treatment （

＜0.05）， but there were no statistically significant differences among those groups （

＞0.05）. The total effective rates of traditional Chinese medicine syndrome efficacy in groups A， B and C were 67.5%， 80.0% and 87.5%， respectively， with group C being significantly higher than group A （

＜0.05）.

CONCLUSIONS

In addition to conventional treatment， ticagrelor combined with Compound xueguantong capsules can more significantly reduce the frequency of angina attacks in patients with unstable angina pectoris， reduce the levels of FBG and D-dimer， improve traditional Chinese medicine syndrome efficacy， and do not increase the risk of bleeding.

关键词

不稳定型心绞痛替格瑞洛复方血栓通胶囊心绞痛发作次数

Keywords

ticagrelorCompound xueshuantong capsulefrequency of angina attacks

references

WHO. World Health Statistics 2018[EB/OL]. （2018-06-06）[2023-03-18]. http：//apps.who.int/iris/bitstream/handle/10665/272596/9789241565585-eng.pdf?ua=1http://apps.who.int/iris/bitstream/handle/10665/272596/9789241565585-eng.pdf?ua=1.

BHATT D L，LOPES R D，HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes：a review[J]. JAMA，2022，327（7）：662-675.

LUN R，DHALIWAL S，ZITIKYTE G，et al. Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack：a network meta-analysis[J]. JAMA Neurol，2022，79（2）：141-148.

申永艳，何贵新，肖婷，等. 不稳定型心绞痛中西医结合诊疗新进展[J]. 大众科技，2019，21（11）：51-53，68.

SHEN Y Y，HE G X，XIAO T，et al. New progress in treatment of unstable angina pectoris with integrated traditional Chinese and western medicine[J]. Pop Sci Technol，2019，21（11）：51-53，68.

WU M，YANG S J，LIU G J，et al. Treating unstable angina with detoxifying and blood-activating formulae：a randomized controlled trial[J]. J Ethnopharmacol，2021，281：114530.

中华医学会心血管病学分会，中华心血管病杂志编辑委员会. 非ST段抬高型急性冠状动脉综合征诊断和治疗指南：2016[J]. 中华心血管病杂志，2017，45（5）：359-376.

Chinese Society of Cardiology，Editorial Board of Chinese Journal of Cardiovascular Diseases. Guidelines for diagnosis and treatment of non-ST-segment elevation acute coronary syndrome：2016[J]. Chin J Cardiol，2017，45（5）：359-376.

COLLET J P，THIELE H，BARBATO E，et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Rev Esp Cardiol，2021，74（6）：544.

中国医师协会中西医结合医师分会，中国中西医结合学会心血管病专业委员会，中国中西医结合学会重症医学专业委员会，等. 急性心肌梗死中西医结合诊疗指南[J]. 中国中西医结合杂志，2018，38（3）：272-284.

The Branch of Integrated Traditional Chinese and Western Medicine Physicians of the Chinese Medical Association，the Cardiovascular Disease Professional Committee of the Chinese Association of Integrated Traditional Chinese and Western Medicine， the Critical Care Medicine Professional Committee of the Chinese Association of Integrated Traditional Chinese and Western Medicine，et al. Guidelines for the diagnosis and treatment of acute myocardial infarction by combining traditional Chinese and western medicine[J]. Chin J Integr Tradit West Med，2018，38（3）：272-284.

MOSS A，DAGHEM M，TZOLOS E，et al. Coronary atherosclerotic plaque activity and future coronary events[J]. JAMA Cardiol，2023，8（8）：755-764.

郑筱萸. 中药新药临床研究指导原则：试行[M]. 北京：中国医药科技出版社，2002：383.

ZHENG X Y. Guiding principles for clinical research of new traditional Chinese medicine：trial implementation [M]. Beijing：China Medical Science and Technology Press，2002：383.

FANG J Y，ZHANG X L. Effect of various doses of rosu- vastatin in the treatment of elderly patients with unstable angina pectoris[J]. Am J Transl Res，2022，14（1）：594-602.

XUE Y，HU Z H，JING Y K，et al. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches[J]. J Clin Pharm Ther，2020，45（5）：1076-1086.

LI Y Z，TAO T Q，SONG D D，et al. Effects of Xuefu zhuyu granules on patients with stable coronary heart di- sease：a double-blind，randomized，and placebo-controlled study[J]. Oxid Med Cell Longev，2021，2021：8877296.

LIU H，LIANG J P，LI P B，et al. Core bioactive components promoting blood circulation in the traditional Chinese medicine compound Xueshuantong capsule （CXC） based on the relevance analysis between chemical HPLC fingerprint and in vivo biological effects[J]. PLoS One，2014，9（11）：e112675.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据